In The Lancet in 1971, Julian Tudor Hart gave medicine one of its most important insights: the availability of medical care ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

When you're setting out to get a new gaming PC or laptop, you've probably noticed there are quite a few models out there without an Nvidia or AMD graphics chip. These devices usually come with an ...

It’s hard to ignore the seismic shifts brought about by algorithm-driven content. Every time you scroll through your social media feed or check your favorite news app, algorithms are diligently at ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...